Twist continues to invest in NGS while growing its core synthetic biology business, and has filed a countercomplaint in its ongoing litigation with Agilent.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
